Background Only clinically validated HPV assays can be accepted in cervical cancer
screening. Objectives To update the list of high-risk HPV assays that fulfil the 2009 international …

Purpose To provide evidence-based, resource-stratified global recommendations to clinicians
and policymakers on the management and palliative care of women diagnosed with …

To evaluate the Turkey's nationwide HPV DNA screening program on the basis of first 1
million screened women. Women over age 30 were invited for population based screening via …

The age‐standardised incidence of cervical cancer in Europe varies widely by country (between
3 and 25/100000 women‐years) in 2018. Human papillomavirus (HPV) vaccine …

To assess the correlation between functional and anatomical evaluations with multifocal
electroretinography (mfERG) and spectral-domain optical coherence tomography (SD-OCT) in …

Purpose In December 2019, the emerging of a novel coronavirus (COVID-19) has influenced
the whole world. The current pandemic also triggers several psychological changes. …

Cervical cancer is the fourth most common cancer among women globally, with an estimated
570 000 new cases and 311 000 deaths worldwide in 2018. 1–3 The highest regional …

Background The impact of the COVID‐19 pandemic on European gynaecological cancer
patients under active treatment or follow‐up has not been documented. We sought to capture …

Background Cervical cancer screening tests that identify DNA of the main causal agent, high-risk
human papillomavirus (HPV) types, are more protective than cervical cytology. We …

This paper summarises the position of ESGO and EFC on cervical screening based on existing
guidelines and opinions of a team of lead experts. HPV test is replacing cytology as this …